Supernus Pharmaceuticals (LTS:0LB2) Institutional Ownership: 63.99% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $47.48
GF Value $41.57
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Institutional Ownership?

Supernus Pharmaceuticals LTS:0LB2 -1.15% 88 Institutional Ownership is 63.99% as of Jul. 15, 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $41.57 (Modestly Overvalued).

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Supernus Pharmaceuticals's institutional ownership is 63.99%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Supernus Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Supernus Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 81.41%.

Supernus Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Institutional Ownership Chart

Supernus Pharmaceuticals Historical Data

The historical data trend for Supernus Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 65.18 65.24 63.81 64.01 63.31 63.99 64.77 63.04 63.40 63.99
LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 63.99% mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Institutional Ownership of 63.99% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Institutional Ownership too high?
Supernus Pharmaceuticals' current Institutional Ownership is 63.99%. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Institutional Ownership compare to BCRX and PBH?
Supernus Pharmaceuticals' Institutional Ownership of 63.99% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Institutional Ownership is 63.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $41.57, compared to a current price of $47.48 — trading 14.2% above its estimated fair value. The current Institutional Ownership is 63.99%. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Institutional Ownership is 63.99% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $47.48 is trading 14.2% above its estimated GF Value™ of $41.57. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Institutional Ownership: 63.99%
  • GF Value™: $41.57 vs. price of $47.48 (14.2% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.48
Price
$41.57
GF Value